Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma
- 1 November 1982
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 21 (3) , 159-161
- https://doi.org/10.1002/jso.2930210305
Abstract
Ten patients with advanced ovarian carcinoma were treated with hexa‐methylmelamine and melphalan after failing first‐line combination chemotherapy. In eight patients residual disease was evident only at second‐look laparotomy. Surgical debulking was accomplished in four patients but only two patients had residual disease of less than 2 cm. Two of these four patients are alive without evidence of disease at 20 and 24 months. The remaining patients have expired (median survival 6 months). The combination of hexamethylmelamine and melphalan after surgical debulking at second‐look operation may improve the salvage of patients with advanced ovarian carcinoma.Keywords
This publication has 6 references indexed in Scilit:
- CYCLOPHOSPHAMIDE, HEXAMETHYLMELAMINE, DOXORUBICIN, AND CISPLATIN (CHAD) AS 2ND-LINE CHEMOTHERAPY FOR OVARIAN ADENOCARCINOMA1981
- Ovarian CancerPublished by American Medical Association (AMA) ,1979
- Ovarian cancer. Effective treatment after alkylating-agent failureJAMA, 1979
- HEXAMETHYLMELAMINE IN OVARIAN-CANCER RESISTANT TO CYCLOPHOSPHAMIDE AND ADRIAMYCIN1979
- Chemotherapeutic Sensitivity of Minimal Residual Disease Following Surgical Excision of Ovarian CarcinomaPublished by Springer Nature ,1979
- Hexamethylmelamine in alkylating agent-resistant ovarian carcinomaCancer, 1978